Borderline ovarian tumors: twenty years of experience at a tertiary center

Fatih Sahin; Erhan Aktürk; Osman Samet Günkaya; Savaş Özdemir; Merve Konal; Simten Genç; Arzu Yurci; Ozgur Akbayir

Article Details

Borderline ovarian tumors: twenty years of experience at a tertiary center

Authors:

Fatih Sahin | Erhan Aktürk | Osman Samet Günkaya | Savaş Özdemir | Merve Konal | Simten Genç | Arzu Yurci | Ozgur Akbayir

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Kadın Hastalıkları ve Doğum | Sağlık Kurumları Yönetimi

Journal:

Anatolian Current Medical Journal Vol.5 Issue 3, pp.196-200

Document Type:

Article

Publication Date:

7/2023

Document Language:

English

Document ID (Org No.):

2001293468

pISSN:

2718-0115

Keywords:

Abstract:

 Aims: To investigate whether there is a difference between serum tumor markers panel CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA and tumor size and histopathology in well-staged patients with borderline ovarian tumors BOTs. Methods: Over the past 20 years January 2001 to January 2021, the results of four tumor markers CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA have been clinically analyzed for for this retrospective cohort study of 156 patients who underwent surgery and were diagnosed with histopathology consistent with a borderline ovarian tumor. Results: The average age of patients with borderline ovarian tumors was determined to be 51.67 4.726 years. Before the first surgery, high CA 125 levels 35 Ul were found in 53 patients 34, high CEA levels 4 ngml were found in 24 patients 15.4, high CA 19-9 levels 37 Uml were found in 29 patients 18.6, and high CA 15-3 30 ngml levels were found in 12 patients 7.7. The average CA 125 levels in tumors with serous histopathology 372.8 1805.2 were higher than those in tumors with mucinous histopathology p0.006. There was no statistically significant difference in tumor markers between tumors smaller than 8 cm and larger than 8 cm CA 125 p0,257, CEA p0.9, CA 19-9 p0.295, CA 15-3 p0.404. Conclusion: Our primary outcome of the study is an increase in CA 125 levels, which indicates serous histopathology. Our secondary outcome is the higher levels of tumor markers, but it does not suggest larger tumors.

 Aims: To investigate whether there is a difference between serum tumor markers panel CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA and tumor size and histopathology in well-staged patients with borderline ovarian tumors BOTs. Methods: Over the past 20 years January 2001 to January 2021, the results of four tumor markers CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA have been clinically analyzed for for this retrospective cohort study of 156 patients who underwent surgery and were diagnosed with histopathology consistent with a borderline ovarian tumor. Results: The average age of patients with borderline ovarian tumors was determined to be 51.67 4.726 years. Before the first surgery, high CA 125 levels 35 Ul were found in 53 patients 34, high CEA levels 4 ngml were found in 24 patients 15.4, high CA 19-9 levels 37 Uml were found in 29 patients 18.6, and high CA 15-3 30 ngml levels were found in 12 patients 7.7. The average CA 125 levels in tumors with serous histopathology 372.8 1805.2 were higher than those in tumors with mucinous histopathology p0.006. There was no statistically significant difference in tumor markers between tumors smaller than 8 cm and larger than 8 cm CA 125 p0,257, CEA p0.9, CA 19-9 p0.295, CA 15-3 p0.404. Conclusion: Our primary outcome of the study is an increase in CA 125 levels, which indicates serous histopathology. Our secondary outcome is the higher levels of tumor markers, but it does not suggest larger tumors.

 Aims: To investigate whether there is a difference between serum tumor markers panel CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA and tumor size and histopathology in well-staged patients with borderline ovarian tumors BOTs. Methods: Over the past 20 years January 2001 to January 2021, the results of four tumor markers CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA have been clinically analyzed for for this retrospective cohort study of 156 patients who underwent surgery and were diagnosed with histopathology consistent with a borderline ovarian tumor. Results: The average age of patients with borderline ovarian tumors was determined to be 51.67 4.726 years. Before the first surgery, high CA 125 levels 35 Ul were found in 53 patients 34, high CEA levels 4 ngml were found in 24 patients 15.4, high CA 19-9 levels 37 Uml were found in 29 patients 18.6, and high CA 15-3 30 ngml levels were found in 12 patients 7.7. The average CA 125 levels in tumors with serous histopathology 372.8 1805.2 were higher than those in tumors with mucinous histopathology p0.006. There was no statistically significant difference in tumor markers between tumors smaller than 8 cm and larger than 8 cm CA 125 p0,257, CEA p0.9, CA 19-9 p0.295, CA 15-3 p0.404. Conclusion: Our primary outcome of the study is an increase in CA 125 levels, which indicates serous histopathology. Our secondary outcome is the higher levels of tumor markers, but it does not suggest larger tumors.

 Aims: To investigate whether there is a difference between serum tumor markers panel CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA and tumor size and histopathology in well-staged patients with borderline ovarian tumors BOTs. Methods: Over the past 20 years January 2001 to January 2021, the results of four tumor markers CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen CEA have been clinically analyzed for for this retrospective cohort study of 156 patients who underwent surgery and were diagnosed with histopathology consistent with a borderline ovarian tumor. Results: The average age of patients with borderline ovarian tumors was determined to be 51.67 4.726 years. Before the first surgery, high CA 125 levels 35 Ul were found in 53 patients 34, high CEA levels 4 ngml were found in 24 patients 15.4, high CA 19-9 levels 37 Uml were found in 29 patients 18.6, and high CA 15-3 30 ngml levels were found in 12 patients 7.7. The average CA 125 levels in tumors with serous histopathology 372.8 1805.2 were higher than those in tumors with mucinous histopathology p0.006. There was no statistically significant difference in tumor markers between tumors smaller than 8 cm and larger than 8 cm CA 125 p0,257, CEA p0.9, CA 19-9 p0.295, CA 15-3 p0.404. Conclusion: Our primary outcome of the study is an increase in CA 125 levels, which indicates serous histopathology. Our secondary outcome is the higher levels of tumor markers, but it does not suggest larger tumors.

Article Details

Borderline ovarian tumors: twenty years of experience at a tertiary center

Authors:

Fatih Sahin | Erhan Aktürk | Osman Samet Günkaya | Savaş Özdemir | Merve Konal | Simten Genç | Arzu Yurci | Ozgur Akbayir

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Kadın Hastalıkları ve Doğum | Sağlık Kurumları Yönetimi

Journal:

Anatolian Current Medical Journal Vol.5 Issue 3, pp.196-200

Document Type:

Article

Publication Date:

7/2023

Document Language:

English

Document ID (Org No.):

2001293468

pISSN:

2718-0115

Borderline epithelial ovarian tumors

tumor markers

CA 125Borderline epithelial ovarian tumors

tumor markers

CA 125

Issues

Article Details

Borderline ovarian tumors: twenty years of experience at a tertiary center

Authors: Fatih Sahin | Erhan Aktürk | Osman Samet Günkaya | Savaş Özdemir | Merve Konal | Simten Genç | Arzu Yurci | Ozgur Akbayir

Publisher: MediHealth Academy Yayıncılık

Main Topics: Kadın Hastalıkları ve Doğum | Sağlık Kurumları Yönetimi

Journal: Anatolian Current Medical Journal Vol.5 Issue 3, pp.196-200

Document Type: Article

Publication Date: 7/2023

Document Language: English

Document ID (Org No.): 2001293468

pISSN: 2718-0115

Borderline epithelial ovarian tumors

tumor markers

CA 125Borderline epithelial ovarian tumors

tumor markers

CA 125

Issues

Authors:

Fatih Sahin | Erhan Aktürk | Osman Samet Günkaya | Savaş Özdemir | Merve Konal | Simten Genç | Arzu Yurci | Ozgur Akbayir

Publisher:

MediHealth Academy Yayıncılık

Main Topics:

Kadın Hastalıkları ve Doğum | Sağlık Kurumları Yönetimi

Journal:

Anatolian Current Medical Journal Vol.5 Issue 3, pp.196-200

Document Type:

Article

Publication Date:

7/2023

Document Language:

English

Document ID (Org No.):

2001293468

pISSN:

2718-0115